Re: Post market showing up 1.94 to 24.43
None of us really knows about IPLEX. I was meeting with a friend this week whose mother-in-law has been diagnosed with ALS. I told him about IPLEX, the history, etc. and he was so enthused about checking out INSM, and planned to buy shares, even though no guarantees with the IPLEX development. It seems to me that even if it is dead to INSM that an FDA-approved drug for short stature, and possibly ALS, with other possible applications, would have some kind of value to some company. I still like to think it is an untapped asset. And, if I remember correctly, it actually was superior to Increlex. Not counting on it, but not discounting it, either.
Lee